Page 2 - Onxeo Sa Euronext News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Onxeo sa euronext. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Onxeo Sa Euronext Today - Breaking & Trending Today

Onxeo: Publication of the 2022 Annual Financial Report

Regulatory News:

Onxeo S.A. , hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor. | April 28, 2023 ....

France General , Onxeo Sa Euronext , Regulatory News , Euronext Growth Paris , Onxeo Stock Exchange , Press Release , Argeting Alonx Fr0010095596 ,

Onxeo: Publication of the 2022 Annual Financial Report

Onxeo: Publication of the 2022 Annual Financial Report
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France General , Nicolas Fossiez , Arthur Rouill , Onxeo Sa Euronext , Euronext Growth Paris , Strategic Communication ,

Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates

Phase 1b/2 trial of AsiDNA™ in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant prostate cancer continues to enroll. | April 24, 2023 ....

United States , San Antonio , France General , Shefali Agarwal , Institut Curie , Julien Miara , Gustave Roussy , Judith Greciet , Onxeo Sa Euronext , Danielle Guyot Caparros , Marie Dutreix Institut Curie , Drug Administration , Gilles Favre Toulouse Cancer Research Center , Company Group , Anticancer Therapies Congress , European Union , American Association For Cancer Research , Regulatory News , Euronext Growth Paris , Investigational New Drug , Gustave Roussy Cancer Campus , Anticancer Therapies , American Association , Cancer Research , Annual Meeting , Gilles Favre ,

Onxeo S.A.: Onxeo will publish its full-year results on April 24, 2023

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and ....

France General , Onxeo Sa Euronext , Onis Onxeo , Nicolas Fossiez , Arthur Rouill , Company Group , Regulatory News , Euronext Growth Paris , Monday April ,

Onxeo will publish its full-year results on April 24, 2023

Regulatory News:

Onxeo S.A. , a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response and driver oncogenes, today announced. | April 21, 2023 ....

France General , Onxeo Sa Euronext , Regulatory News , Euronext Growth Paris , Monday April , Onxeo Stock Exchange , Press Release , Oday Alonx Fr0010095596 ,